Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Other Clear all
Completed Phase 3 Interventional

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

NCT04578756
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
Interventions
Cariprazine Flexible Dose
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
40
States / cities
Dothan, Alabama • Bentonville, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Phase 2 Interventional

Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors

NCT00006456
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Not applicable Interventional Results available

rTMS in First Episode Psychosis

NCT02131129
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
rTMS, Sham Comparator
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

NCT00390429
View directory record Official record
Conditions
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel, erlotinib hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Schizophrenia Efficacy and Safety Study

NCT01911429
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 40 mg, Lurasidone 80 mg, Placebo 40 or 80 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
36
States / cities
Dothan, Alabama • Anaheim, California • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 8, 2026, 9:13 AM EDT
Completed No phase listed Observational

COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)

NCT04818853
View directory record Official record
Conditions
Covid19, Aspergillosis, Fungal Infection
Interventions
Observation to monitor patients for these infections
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia

NCT05463770
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Long Beach, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 8, 2026, 9:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Angiogenic/Angiostatic Mediators in Patients With Systemic Sclerosis

NCT00668473
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

NCT01909466
View directory record Official record
Conditions
Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions
Aripiprazole, OPC-14597
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Cerritos, California • Garden Grove, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Not applicable Interventional

Reverse Shoulder Replacement: Formal vs. Home Physiotherapy

NCT03430167
View directory record Official record
Conditions
Shoulder Arthropathy Associated With Other Conditions
Interventions
home therapy, formal therapy
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
61 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Phase 1 Interventional

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

NCT05848700
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

NCT01952132
View directory record Official record
Conditions
Schizophrenia
Interventions
OMS643762, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Sep 8, 2026, 9:13 AM EDT
Recruiting Phase 2Phase 3 Interventional

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

NCT06712316
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
40
States / cities
Birmingham, Alabama • Anchorage, Alaska • Concord, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Not applicable Interventional

A Study of Strategies to Improve Schizophrenia Treatment

NCT00156637
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Team-Based Quality Improvement Intervention, Opinion Leader Intervention, Team Based Quality Improvement
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Fayetteville, Arkansas • No. Little Rock, Arkansas • Dayton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 8, 2026, 9:13 AM EDT
Terminated Phase 2 Interventional Results available

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases

NCT00589602
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Secondary Myelofibrosis
Interventions
peripheral blood lymphocyte therapy, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation (TBI)
Procedure · Radiation
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 8, 2026, 9:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Not applicable Interventional Results available

Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine

NCT00512070
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity, Metabolic Syndrome
Interventions
olanzapine and melatonin
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Sep 8, 2026, 9:13 AM EDT
Recruiting Not applicable Interventional

Innovations in Personalizing Treatment Study

NCT06208605
View directory record Official record
Conditions
Eating Disorders
Interventions
Transdiagnostic Network Informed Personalized Treatment, Enhanced Cognitive Behavioral Therapy for Eating Disorders
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 65 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Not applicable Interventional Results available

Cognitive Rehabilitation in Schizophrenia

NCT00248794
View directory record Official record
Conditions
Cognitive Impairment, Schizophrenia
Interventions
Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG), Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG), Skills Group (SDG)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Phase 1 Interventional Results available

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

NCT00379639
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Romidepsin, Gemcitabine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 8, 2026, 9:13 AM EDT
Terminated Phase 1 Interventional

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

NCT05429502
View directory record Official record
Conditions
Neuroblastoma
Interventions
Topotecan, Temozolomide, Ribociclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • New Hyde Park, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 8, 2026, 9:13 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

NCT03896945
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

NCT06706869
View directory record Official record
Conditions
Healthy
Interventions
PF-07258669, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 8, 2026, 9:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

BE Technologies Mobile Uroflowmetry Validation Study

NCT04599283
View directory record Official record
Conditions
BPH, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms, BPH Without Urinary Obstruction, BPH Without Urinary Obstruction With Other Lower Urinary Tract Symptoms, Lower Urinary Tract Symptoms, Overactive Bladder, Overactive Bladder Syndrome, Urinary Obstruction, Urinary Incontinence, Urge
Interventions
MenHealth Uroflowmeter
Device
Lead sponsor
BE Technologies Inc
Industry
Eligibility
18 Years to 90 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 8, 2026, 9:13 AM EDT